EMA recommends approval of letermovir for CMV in stem cell transplant recipients

El acceso al contenido completo es sólo para profesionales sanitarios registrados. Regístrate para leer más

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for letermovir (Prevymis), an antiviral that prevents cytomegalovirus (CMV) reactivation and disease in patients receiving im...